NCT02607618 - Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2 | Biotech Hunter

Enrollment

613

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

August 8, 2017

Study Completion Date

August 8, 2017

Conditions

Skin Structures and Soft Tissue Infections

Interventions

DRUG

Iclaprim

Experimental treatment

DRUG

Vancomycin

Active comparator

Trial Locations (54)

1000

Belgium, Brussels

1070

Belgium, Brussels

1085

Hungary, Budapest

3529

Hungary, Miskolc

6720

Hungary, Szeged

8000

Hungary, Székesfehérvár

8200

Hungary, Veszprém

9100

Turkey, Aydin

10000

Croatia, Zagreb

13419

Estonia, Tallinn

20475

Romania, Bucharest

23000

Croatia, Zadar

31025

Estonia, Kohtla-Järve

31419

Estonia, Tallinn

31904

Georgia, Columbus

33021

Florida, Hollywood

33130

Florida, Miami

34098

Turkey, Istanbul

35000

Croatia, Slavonski Brod

41914

Romania, Bucharest

42122

Romania, Bucharest

45801

Ohio, Lima

50098

Romania, Bucharest

51014

Estonia, Tartu

59701

Montana, Butte

61080

Turkey, Trabzon

65526

Estonia, Võru

70852

Czech Republic, Ostrava

89109

Nevada, Las Vegas

90620

California, Buena Park

90623

California, La Palma

90813

California, Long Beach

St. Mary Medical Center ER, Long Beach

91911

California, Chula Vista

92804

California, Anaheim

99336

Washington, Kennewick

99352

Washington, Richland

200642

Romania, Craiova

300736

Romania, Timișoara

310037

Romania, Arad

400162

Romania, Cluj-Napoca

33130-2433

Florida, Miami

08244

New Jersey, Somers Point

37167-6826

Tennessee, Smyrna

C1425DQK

Argentina, Buenos Aires

C1430BKC

Argentina, Buenos Aires

500 05

Czech Republic, Hradec Králové

261 01

Czech Republic, Příbram

400 11

Czech Republic, Ústí nad Labem

2720-276

Portugal, Amadora

4710-243

Portugal, Braga

4200-319

Portugal, Porto

2005-177

Portugal, Santarém

4901-858

Portugal, Viana do Castelo